



SUMMARY OF SUBGROUP DECISIONS FOR GMMMG APPROVAL – 10th March 2022

SUBGROUP DECISIONS WITH SIGNIFICANT FINANCIAL OR COMMISSIONING IMPACT

CRG DECISIONS November 2021

Product and indication	Status Assigned	Include in formulary	Notes on Decision	Cost impact	Commissioning/ Service implications	GMMMG decision
Trurapi – Insulin aspart biosimilar	GREEN	Add to chapter 6.1.1.1 as first line rapid acting insulin	Trurapi is a biosimilar of Novorapid and has demonstrated comparable efficacy and safety to the reference product. It costs £19.82 for 5 x 3mL cartridges, or £21.42 for 5 x 3mL pre-filled pens which is 30% less than the equivalent Novorapid products. CRG recommended that Trurapi should replace Apidra and Insulin Lispro as the first choice rapid acting insulin analogue for the treatment of diabetes mellitus in adults, adolescents and children aged >1 year of age. A largescale switch from Novorapid to Trurapi is not advocated by CRG, but they support an individual patient level switch, in line with NICE NG17 , following a shared decision making process with the patient and/or carer.	Potential savings of £1.1m per year in GM if a switch is implemented from Novorapid.	None identified	Approved
Haloperidol 500microgram tablets	DNP – criterion 2	Amend chapter 4.2.1	CRG noted the large price increases for this product, following the discontinuation of Serenace in 2020, and agreed to assign DNP status as criterion 2: Drug is clinically effective but more cost-effective products are available. This includes products that have been subject to excessive price inflation. 28 x 500microgram tablets are currently priced at £148.21 and 5mg/5mL and 10mg/5mL haloperidol oral solution preparations are more	Total annual spend on haloperidol 500microgram tablets Sep 20 – Aug 21 was £926k. There is potential to save £880k per year with a	None identified	Approved

			cost effective; £6.48 and £7.10 for 100mL respectively (all prices from Nov 21 Drug Tariff) CRG did not believe there to be any clinical concerns in recommending a switch to the oral liquid.	complete switch to haloperidol 5mg/5ml liquid		
--	--	--	---	---	--	--

SUBGROUP DECISIONS WITHOUT SIGNIFICANT FINANCIAL OR COMMISSIONING IMPACT

CRG DECISIONS October 2021

Product and indication	Status Assigned	Include in formulary	Notes on Decision	Cost impact	Commissioning/ Service implications	FINAL DECISION
TA738 : Berotralstat for preventing recurrent attacks of hereditary angioedema	RED with link to TA738	Yes	<p>Commissioning: NHSE Berotralstat is recommended as an option for preventing recurrent attacks of hereditary angioedema in people 12 years and older, only if:</p> <ul style="list-style-type: none"> they have at least 2 attacks per month, and it is stopped if the number of attacks per month does not reduce by at least 50% after 3 months. <p>It is only recommended if the company provides berotralstat according to the commercial arrangement.</p>	N/A	N/A	Approved
Casirivimab/imdevimab (Ronapreve®) for COVID-19 as per NG191: COVID-19 rapid guideline: managing COVID-19	RED with link to NG191	Yes – already added	<p>Commissioning: NHSE For information; already added to formulary. To be used as per current recommendations in NG191.</p>	N/A	N/A	Approved

All links to MHRA drug safety updates added to formulary as published. Significant alerts where further action is required are highlighted.